Genentech And The Use Of Lucentis And Avastin For Ophthalmic Purposes

EDM number 2823 in 2010-12, proposed by John Hemming on 06/03/2012.

That this House notes the positive clinical results from the use of Lucentis for ophthalmic uses; further notes that Avastin has also been found to be efficacious for similar purposes; further notes that Genentech, the manufacturer of both, has resisted the clinical use of Avastin in an ophthalmic setting; queries whether the fact that Lucentis has a cost of the order of 40 times the cost of Avastin is a matter which is influencing the manufacturer; and calls on Health Ministers to enter into discussions with Genentech as to how most effectively patients in England can have their ophthalmic issues properly medicated.

This motion has been signed by a total of 3 MPs.